SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending sharply following reports of an upcoming partnership with Novo Nordisk to sell obesity drugs, signaling an end to their prior legal dispute. The unexpected collaboration has the community actively discussing the potential for a significant short squeeze, given the stock's high short interest, and anticipating substantial upside.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a surprise partnership announcement with Hims & Hers to distribute its obesity drugs, ending a prior feud. The community is actively discussing the substantial surge in Hims' stock compared to Novo Nordisk's more modest reaction, raising questions about the deal's implications for the GLP-1 market and competitive landscape.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community celebrates the imminent departure of a prominent FDA official, widely seen as a significant barrier to the approval of its Duchenne Muscular Dystrophy therapy, Deramiocel. This development, coupled with high anticipation for a late-breaking Phase 3 data presentation at a major medical conference, is fueling intense bullish sentiment and expectations for a rapid regulatory decision.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure (QURE) is experiencing a sharp rebound, driven by the departure of a controversial FDA official, which the community speculates could pave an easier regulatory path for its Huntington's disease gene therapy and is currently fueling a short squeeze.

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals ($DAWN) is trending after agreeing to be acquired by Servier for $21.50 per share in cash, a deal valued at approximately $2.5 billion that offers a significant premium. The community is celebrating substantial gains, with many noting how patience and conviction paid off amidst previous buyout speculation and a recent massive volume spike.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to significant community optimism following reports of Dr. Vinay Prasad's departure from the FDA, which many believe will foster a more permissive regulatory environment for gene therapies. This development, coupled with CEO Doug Ingram's announced retirement, is fueling M&A speculation and anticipation for upcoming DM1 and FSHD data.

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

ClearPoint Neuro Inc

ClearPoint Neuro is trending sharply following positive news from its partner uniQure's Huntington's disease gene therapy, highlighting ClearPoint's essential precision delivery technology and fueling community excitement about its diverse pipeline in neurological treatments.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as it announces a $300 million restructuring charge, fueling speculation among investors about a potential exit from its struggling Converse brand. The community remains divided, with many concerned about ongoing margin pressures and the slow pace of a turnaround, while others see a long-term buying opportunity despite confusing price action around recent tariff news.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its recent expansion into U.S.-made regulated lab products for the pharmaceutical sector, igniting community speculation about potential government contracts aimed at securing domestic API and KSM supply chains amidst global geopolitical concerns. Investors anticipate a significant revaluation for the diversified materials science company, though some express frustration over management's communication regarding these developments.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Warrior Met Coal $HCC Shares Sold by Citigroup Inc.

Citigroup Inc. cut its holdings in shares of Warrior Met Coal (NYSE:HCC - Free Report) by 31.5% during the third quarter, according to the company in its most recent Form 13F filing with the...

JPMorgan Chase & Co. Has $16.61 Million Position in Warrior Met Coal $HCC

JPMorgan Chase & Co. cut its stake in shares of Warrior Met Coal (NYSE:HCC - Free Report) by 6.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Warrior Met Coal $HCC Stake Lifted by Kennondale Capital Management LLC

Kennondale Capital Management LLC grew its stake in shares of Warrior Met Coal (NYSE:HCC - Free Report) by 42.6% in the third quarter, according to its most recent filing with the Securities...

American Century Companies Inc. Lowers Position in Warrior Met Coal $HCC

American Century Companies Inc. decreased its stake in shares of Warrior Met Coal (NYSE:HCC - Free Report) by 8.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The...

Warrior Met Coal $HCC Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its holdings in shares of Warrior Met Coal (NYSE:HCC - Free Report) by 1.2% in the third quarter, according to the company in its most recent filing with the Securities...

57,362 Shares in Warrior Met Coal $HCC Bought by Waratah Capital Advisors Ltd.

Waratah Capital Advisors Ltd. bought a new stake in Warrior Met Coal (NYSE:HCC - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and...

Warrior Met Coal (NYSE:HCC) Given Consensus Rating of "Hold" by Analysts

Warrior Met Coal (NYSE:HCC - Get Free Report) has been assigned an average rating of "Hold" from the six analysts that are covering the firm, MarketBeat reports. One equities research analyst has...

Implied Volatility Surging for Warrior Met Coal Stock Options

Investors need to pay close attention to Warrior Met Coal stock based on the movements in the options market lately.

Persistent Asset Partners Ltd Has $236,000 Holdings in Warrior Met Coal $HCC

Persistent Asset Partners Ltd trimmed its holdings in Warrior Met Coal (NYSE:HCC - Free Report) by 77.1% in the third quarter, according to the company in its most recent Form 13F filing with the...

Warrior Publishes 2025 Corporate Responsibility Report

Warrior Met Coal, Inc. (NYSE: HCC) (Warrior or the Company) announced the publication of its 2025 Corporate Responsibility Report, now available for download on the Companys website at...

Warrior Met Coal, Inc. engages in the production and export of metallurgical coal. It is focused on mining non-thermal steelmaking coal used as a component of steel production by metal manufacturers in Europe, South America and Asia. The company was founded on September 3, 2015 and is headquartered in Brookwood, AL.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.84	--	--	N/A
Q4 '25	$0.50	$0.43	-15.45%	MISSED
Q3 '25	-$0.31	$0.70	328.57%	BEAT
Q2 '25	-$0.36	$0.11	130.32%	BEAT
Q1 '25	-$0.05	-$0.16	-247.83%	MISSED

HCC
Warrior Met Coal Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest HCC News

HCCWarrior Met Coal Inc